Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation

Area of Science:

• Pulmonary Medicine
• Nanotechnology in Drug Delivery
• Immunology

Background:

• Systemic glucocorticoids treat lung inflammation but cause side effects.
• Liposomal drug delivery offers localized treatment potential.
• Targeting Fcγ-receptors (FcγRs) may enhance liposome efficacy.

Purpose of the Study:

• To investigate if liposome-encapsulated dexamethasone inhibits ventilator-induced lung inflammation.
• To evaluate if FcγR-targeted liposomes improve dexamethasone efficacy in reducing granulocyte infiltration.

Main Methods:

• Mice were mechanically ventilated with low (LV(T)) or high (HV(T)) tidal volumes.
• Intravenous administration of dexamethasone-liposomes (Dex-liposomes), IgG-modified dexamethasone-liposomes (IgG-Dex-liposomes), or free dexamethasone.
• Assessment of granulocyte infiltration and inflammatory mediator mRNA expression.

Main Results:

• Dex-liposomes attenuated inflammation in LV(T) but not HV(T) ventilation.
• IgG-Dex-liposomes significantly inhibited granulocyte influx in both LV(T) and HV(T) groups.
• Free dexamethasone also prevented inflammation; IgG-Dex-liposomes showed comparable efficacy with localized delivery.

Conclusions:

• FcγR-targeted IgG-Dex-liposomes are more effective than non-targeted liposomes for inhibiting lung inflammation.
• IgG-Dex-liposomes provide localized lung delivery, potentially minimizing systemic side effects.
• Targeted liposomal dexamethasone demonstrates significant therapeutic potential for ventilator-induced lung injury.